A5095370490- Monoclonal and Polyclonal Antibodies Research
- Radiopharmaceutical Chemistry and Applications
- Glycosylation and Glycoproteins Research
- HER2/EGFR in Cancer Research
- Advanced biosensing and bioanalysis techniques
- Nanoparticle-Based Drug Delivery
Uppsala University
2024-2025
Designed ankyrin repeat protein (DARPin) G3 is an engineered scaffold protein. This small (14.5 kDa) targeting binds with high affinity to human epidermal growth factor receptor 2 (HER2). HER2 overexpressed in several cancers. The use of the DARPin for radionuclide therapy complicated by its renal reabsorption after clearance via glomeruli. We tested hypothesis that a fusion albumin-binding domain (ABD) would prevent rapid excretion and resulting better tumour targeting. Two proteins were...
The immune checkpoint protein B7-H3 (CD276) is overexpressed in various cancers and an attractive target for the treatment of malignant tumors. Radionuclide molecular imaging expression using engineered scaffold proteins such as Affibody molecules a promising strategy selection potential responders to B7-H3-targeted therapy. Feasibility was demonstrated two 99mTc-labeled probes, AC12 affinity-matured SYNT179 [99mTc]Tc-GGGC label. This study aimed evaluate whether use residualizing...
Affibody-mediated PNA-based pretargeting shows promise for HER2-expressing tumor radiotherapy. In our recent study, a 15-mer Z